Free Research Reports on These Biotech Stocks -- Seattle Genetics, Spectrum Pharma, Syros Pharma, and Teligent

Tuesday, February 27, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 27, 2018 /PRNewswire/ -- strives to bring the best free research to the investment

community.  Today we are offering reports on SGEN, SPPI, SYRS, and TLGT which can be accessed for free by signing up to Pre-market, concentrates on the global Biotechnology market, which is
mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases. Biotech finds extensive application in several industries, such as Agriculture, Pharmaceuticals, downstream Chemical Processing, and Bioservices. Companies in this morning's lineup are: Seattle Genetics Inc. (NASDAQ: SGEN), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Syros Pharmaceuticals Inc. (NASDAQ: SYRS), and Teligent Inc. (NASDAQ: TLGT). All you have to do is sign up today for this free limited time offer by clicking the link below.

Seattle Genetics

Bothell, Washington headquartered Seattle Genetics Inc.'s stock finished Monday's session 1.03% higher at $55.92 with a total trading volume of 592,486 shares. Over the last month, the Company's shares have advanced 0.59%. The stock is trading above its 50-day moving average by 3.61%. Moreover, shares of Seattle Genetics, which focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide, have a Relative Strength Index (RSI) of 56.96.  

On February 06th, 2018, Seattle Genetics reported its financial results for the quarter and year ended December 31st, 2017. For Q4 2017, total revenues were $129.6 million, and net loss was $(59.2) million. For the full year 2017, total revenues were $482.3 million, and net loss was $(125.5) million. As of December 31st, 2017, the Company had $413.2 million in cash, cash equivalents and investments, excluding its Immunomedics common stock investment.

On February 14th, 2018, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Get the full research report on SGEN for free by clicking below at:

Spectrum Pharmaceuticals

Shares in Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc. rose slightly by 0.62%, ending yesterday's session at $22.63 with a total trading volume of 1.08 million shares. The stock has gained 1.12% in the past month, 14.87% in the previous three months, and 290.17% over the past year. The Company's shares are trading 13.81% above their 50-day moving average and 67.56% above their 200-day moving average. Moreover, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have an RSI of 63.58. 

On February 05th, 2018, Spectrum Pharma announced that the first Phase-3 study of ROLONTIS, ADVANCE, has met its primary endpoint of non-inferiority in Duration of Severe Neutropenia in comparison to pegfilgrastim. This study evaluated the safety and efficacy of ROLONTIS in the management of chemotherapy-induced neutropenia in 406 patients with early-stage breast cancer. The Company also announced that RECOVER, the second Phase-3 study, has completed enrollment. Find your free research report SPPI at:

Syros Pharmaceuticals

On Monday, Cambridge, Massachusetts-based Syros Pharmaceuticals Inc.'s stock jumped 5.36%, to close the day at $11.01. A total volume of 195,002 shares was traded. The Company's shares have advanced 0.09% in the last month and 0.27% over the past year. The stock is trading 9.04% above its 50-day moving average. Additionally, shares of Syros Pharma, which focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases, have an RSI of 61.10. 

On February 07th, 2018, Syros Pharma announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 628,272 shares at the public offering price of $9.55 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by the Company to 4,816,753 shares and increased the amount of net proceeds raised in the offering to approximately $42.9 million. Sign up today for the free research report on SYRS at:


Shares in Buena, New Jersey-based Teligent Inc. ended the day flat at $3.00. A total volume of 229,347 shares was traded. The stock is trading below its 50-day moving average by 12.54%. Furthermore, shares of Teligent have an RSI of 39.39. 

On February 14th, 2018, Teligent announced that it has received approval of its abbreviated new drug application from the US FDA of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%. This is the Company's first approval for 2018, and its twentieth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. Wall St. Equities' research coverage also includes the downloadable free report on TLGT at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228


CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store